VanEck Pharmaceutical ETF
42 hedge funds and large institutions have $41M invested in VanEck Pharmaceutical ETF in 2013 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 13 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
2% more funds holding
Funds holding: 41 → 42 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
13.86% less ownership
Funds ownership: 31.2% → 17.35% (-14%)
15% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 13
45% less capital invested
Capital invested by funds: $74.3M → $41M (-$33.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$3.65M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$891K |
| 3 |
JP Morgan Chase
New York
|
+$506K |
| 4 |
SB
Suntrust Banks
Atlanta,
Georgia
|
+$167K |
| 5 |
LPL Financial
San Diego,
California
|
+$117K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sandler Capital Management
New York
|
-$18.5M |
| 2 |
AACR
ACR Alpine Capital Research
St. Louis,
Missouri
|
-$12.6M |
| 3 |
GIM
Guild Investment Management
Los Angeles,
California
|
-$3.19M |
| 4 |
PI
Placemark Investments
Chicago,
Illinois
|
-$2.08M |
| 5 |
MIM
Macroview Investment Management
Bethesda,
Maryland
|
-$1.79M |
PPH Hedge Fund Activity: Q3 2013 in Review
42 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q3 2013, worth a combined $41M — down 45% from $74.3M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new PPH positions and 4 closed out — a net gain of 1 holder — while 11 added to existing stakes and 13 trimmed.
The largest buyer was Credit Suisse, adding an estimated $3.65M. The largest seller was Sandler Capital Management, exiting entirely with an estimated $18.5M sold.
- 42 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q3 2013, up from 41 in Q2 2013.
- Funds reported $41M of VanEck Pharmaceutical ETF stock for Q3 2013, down 45% quarter-over-quarter.
- 5 funds opened new VanEck Pharmaceutical ETF positions in Q3 2013 and 4 closed out, a net change of +1 holder.
- The largest VanEck Pharmaceutical ETF buyer in Q3 2013 was Credit Suisse, an estimated $3.65M added.
- The largest VanEck Pharmaceutical ETF seller in Q3 2013 was Sandler Capital Management, an estimated $18.5M sold.
Based on aggregated 13F filings for Q3 2013.